Filing Flows › Champions Oncology (CSBR) › Q4 FY25
Champions Oncology (CSBR) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Jul 23, 2025
Champions Oncology (CSBR) reported revenue of $12.4M for the fourth quarter fiscal 2025 (Q4 FY25), -12% from a year earlier and -27% from the quarter before. Operating margin was -16.2%, net loss $1.8M (14.9% of revenue).
Champions Oncology, Q4 FY25: revenue $12.4M (-12% year over year), operating margin -16.2%, net loss $1.8M, operating cash flow $6.9M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.4M | -27% | -12% |
| Operating profit | −$2.0M | -145% | — |
| Net earnings | −$1.8M | -141% | — |
| Operating cash flow | $6.9M | 14× | — |
| Free cash flow | $6.6M | 15× | — |
What changed
Revenue was $12.4M in Q4 FY25, down 12% year over year and down 27% from the previous quarter.
Operating costs exceeded revenue by $2.0M, an operating margin of -16.2%. Total costs grew 1% against a revenue fall of 12%. The fastest-growing cost line was Sales & marketing (+30%). The quarter ended with a net loss of $1.8M, after a profit of $4.5M the previous quarter.
Operating cash flow was $6.9M. Non-cash charges added back $400K of depreciation and amortization and $131K of share-based compensation. Working capital and other items added $8.2M. Capital expenditures of $253K left free cash flow of $6.6M.
Questions
What was Champions Oncology's revenue in the fourth quarter fiscal 2025?
Champions Oncology (CSBR) reported revenue of $12.4M for the fourth quarter fiscal 2025 (Q4 FY25), -12% from a year earlier and -27% from the quarter before.
Was Champions Oncology profitable in the fourth quarter fiscal 2025?
Operating loss was $2.0M (-16.2% of revenue) and net loss $1.8M.
Source: Champions Oncology 10-K on SEC EDGAR.